









Markets
/
Stocks
/
nasdaq-jazz
/

Jazz Pharmaceuticals PLC

JAZZ

128.300USD

-2.890-2.20%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.78BMarket Cap

LossP/E TTM



Jazz Pharmaceuticals PLC

128.300

-2.890-2.20%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

32 / 175

Overall Ranking

126 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 19 analysts

Buy

Current Rating

186.718

Target Price

+42.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Fairly Valued

The company’s latest PE is -19.23, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.76M shares, decreasing 9.21% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.07M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.17.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.20, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.05B, representing a year-over-year increase of 2.14%, while its net profit experienced a year-over-year increase of 526.22%.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

6.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.65

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -19.66, which is -188.30% below the recent high of 17.36 and -107.66% above the recent low of -40.82.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 32/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.53, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Jazz Pharmaceuticals PLC is 183.00, with a high of 230.00 and a low of 147.00.

Score

Industry at a Glance

Previous score

8.53

Change

Support & Resistance

No Data

Analyst Rating

Based on 19 analysts

Buy

Current Rating

186.718

Target Price

+42.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Jazz Pharmaceuticals PLC

JAZZ

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.14, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 136.73 and the support level at 121.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.14

Change

-1.89

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.697

Neutral

RSI(14)

57.165

Neutral

STOCH(KDJ)(9,3,3)

63.598

Neutral

ATR(14)

3.347

Low Volatility

CCI(14)

50.249

Neutral

Williams %R

51.535

Neutral

TRIX(12,20)

0.347

Sell

StochRSI(14)

30.944

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

128.158

Buy

MA10

128.069

Buy

MA20

127.530

Buy

MA50

120.039

Buy

MA100

114.522

Buy

MA200

119.571

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 105.11%, representing a quarter-over-quarter decrease of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 6.07M shares, representing 10.00% of shares outstanding, with 0.57% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.99M

-0.31%

BlackRock Institutional Trust Company, N.A.

5.21M

-0.64%

LSV Asset Management

2.47M

-2.56%

Capital World Investors

1.93M

+0.23%

Dimensional Fund Advisors, L.P.

2.33M

+14.42%

State Street Global Advisors (US)

1.97M

-0.11%

EcoR1 Capital, LLC

1.71M

Fuller & Thaler Asset Management Inc.

1.33M

+41.69%

JP Morgan Asset Management

1.50M

+5.01%

Columbia Threadneedle Investments (US)

1.35M

-9.14%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.08, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.